Oncopeptides AB (FRA:OND) Cyclically Adjusted Book per Share: €0.44 (As of Mar. 2026)


FRA:OND Oncopeptides AB FRA:OND
28 GF Score
Price €0.15
GF Value €0.37
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB Cyclically Adjusted Book per Share?

Oncopeptides AB FRA:OND +5.66% 28 Cyclically Adjusted Book per Share is €0.44 as of Mar. 2026. GuruFocus rates FRA:OND with a GF Score™ of 28/100 and a GF Value™ of €0.37 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Oncopeptides AB's adjusted book value per share for the three months ended in Mar. 2026 was €0.019. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.44 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-01), Oncopeptides AB's current stock price is €0.1457. Oncopeptides AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €0.44. Oncopeptides AB's Cyclically Adjusted PB Ratio of today is 0.33.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Oncopeptides AB was 1.14. The lowest was 0.25. And the median was 0.53.


Oncopeptides AB  (FRA:OND) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Oncopeptides AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.1457/0.44
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Oncopeptides AB was 1.14. The lowest was 0.25. And the median was 0.53.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Oncopeptides AB Cyclically Adjusted Book per Share Related Terms


Oncopeptides AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Oncopeptides AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncopeptides AB Cyclically Adjusted Book per Share Chart

Oncopeptides AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.46

Oncopeptides AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.41 0.46 0.44

FRA:OND vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Oncopeptides AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Cyclically Adjusted PB Ratio falls into.


FRA:OND
28GF Score
Oncopeptides AB FRA:OND
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncopeptides AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncopeptides AB's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.019/133.3862*133.3862
=0.019

Current CPI (Mar. 2026) = 133.3862.

Oncopeptides AB Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 101.019 0.000
201609 0.000 101.138 0.000
201612 0.044 102.022 0.058
201703 0.000 102.022 0.000
201706 0.871 102.752 1.131
201709 0.796 103.279 1.028
201712 0.670 103.793 0.861
201803 0.929 103.962 1.192
201806 0.718 104.875 0.913
201809 0.580 105.679 0.732
201812 0.371 105.912 0.467
201903 0.883 105.886 1.112
201906 0.595 106.742 0.744
201909 1.067 107.214 1.327
201912 0.870 107.766 1.077
202003 0.532 106.563 0.666
202006 0.757 107.498 0.939
202009 0.961 107.635 1.191
202012 0.529 108.296 0.652
202103 0.318 108.360 0.391
202106 1.145 108.928 1.402
202109 0.507 110.338 0.613
202112 0.173 112.486 0.205
202203 0.095 114.825 0.110
202206 0.046 118.384 0.052
202209 0.247 122.296 0.269
202212 0.188 126.365 0.198
202303 0.143 127.042 0.150
202306 0.106 129.407 0.109
202309 0.079 130.224 0.081
202312 0.036 131.912 0.036
202403 -0.005 132.205 -0.005
202406 0.072 132.716 0.072
202409 0.050 132.304 0.050
202412 0.020 132.987 0.020
202503 -0.002 132.825 -0.002
202506 -0.026 133.699 -0.026
202509 0.002 133.482 0.002
202512 -0.020 133.386 -0.020
202603 0.019 133.386 0.019

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.44 mean?
Oncopeptides AB (FRA:OND) has a Cyclically Adjusted Book per Share of €0.44 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Oncopeptides AB and its competitors.
Is Oncopeptides AB's Cyclically Adjusted Book per Share too high?
Oncopeptides AB's current Cyclically Adjusted Book per Share is €0.44. Overall, Oncopeptides AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Oncopeptides AB's Cyclically Adjusted Book per Share of €0.44 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current Cyclically Adjusted Book per Share is €0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.37, compared to a current price of €0.15 — trading 60.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is €0.44. Oncopeptides AB's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current Cyclically Adjusted Book per Share is €0.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncopeptides AB (FRA:OND) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of €0.15 is trading 60.6% below its estimated GF Value™ of €0.37. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for FRA:OND:

  • Cyclically Adjusted Book per Share: €0.44
  • GF Value™: €0.37 vs. price of €0.15 (60.6% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncopeptides AB Business Description

Other Exchanges ONCO:SwedenONCOs:UK0RN4:UK
Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
28GF Score

Get the complete analysis for FRA:OND

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.37
GF Value